Overall Response

(N=71)*

1-year primary analysis1

  • 55% ORR (n=39; 95% CI: 43%, 67%)
    • 37% achieved a CR
    • 18% achieved a PR

2-year follow-up analysis2

  • 54% ORR (n=38; 95% CI: 41%, 66%)
    • 35% achieved a CR
    • 18% achieved a PR
View ORR

DURATION OF RESPONSE

(N=71)*

1-year primary analysis1

  • 21.7-month median DoR
    (range: 0, 24)

2-year follow-up analysis2

  • 34.6-month median DoR
    (95% CI: 21.7, NR)
Discover DoR

NCCN Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend tafasitamab-cxix (MONJUVI) in combination with lenalidomide as a second-line or subsequent therapy option for DLBCL in patients who are not candidates for transplant.3

L-MIND was an open-label, multicenter, single-arm study that evaluated the efficacy and safety of MONJUVI in combination with lenalidomide followed by MONJUVI monotherapy in adult patients with R/R DLBCL (confirmed by central laboratory). Efficacy was established in 71 patients based on best ORR (CR + PR) and DoR, as assessed by an Independent Review Committee using the International Working Group Response Criteria (Cheson 2007).1